Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 2:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 291 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: IVIG Clear all
Completed Phase 4 Interventional Results available

Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID)

NCT03033745
View directory record Official record
Conditions
Primary Immunodeficiency
Interventions
IgPro20
Drug
Lead sponsor
CSL Behring
Industry
Eligibility
2 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
10
States / cities
Birmingham, Alabama • Litchfield Park, Arizona • St. Petersburg, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2020 · Synced Oct 19, 2026, 2:30 PM EDT
Terminated Phase 3 Interventional Results available

Maximizing Outcome of Multiple Sclerosis Transplantation

NCT03342638
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Cyclophosphamide, Mesna, rATG, Methylprednisolone, G-CSF, IVIg, Autologous Stem Cells
Drug · Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 58 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Oct 19, 2026, 2:30 PM EDT
Completed Phase 3 Interventional Results available

IGIV Study for Chronic ITP Patients Ages 3-70

NCT00511147
View directory record Official record
Conditions
Idiopathic Thrombocytopenic Purpura
Interventions
IGIV3I Grifols 10%
Biological
Lead sponsor
Grifols Biologicals, LLC
Industry
Eligibility
3 Years to 70 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
31
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2017 · Synced Oct 19, 2026, 2:30 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis

NCT02473952
View directory record Official record
Conditions
Myasthenia Gravis, Generalized
Interventions
IGIV-C, Placebo
Drug
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years to 85 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
15
States / cities
Phoenix, Arizona • Orange, California • New Haven, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Oct 19, 2026, 2:30 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study of Cytokines in Children With Opsoclonus-Myoclonus Syndrome

NCT00806182
View directory record Official record
Conditions
Opsoclonus-myoclonus Syndrome
Interventions
Not listed
Lead sponsor
National Pediatric Neuroinflammation Organization, Inc.
Other
Eligibility
1 Year to 18 Years
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2016
U.S. locations
1
States / cities
Springfield, Illinois
Source: ClinicalTrials.gov public record
Updated May 23, 2017 · Synced Oct 19, 2026, 2:30 PM EDT
Completed No phase listed Observational

A Safety Study of GAMMAGARD LIQUID (GGL) in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

NCT05363358
View directory record Official record
Conditions
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Interventions
Not listed
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
6,086 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 1, 2023 · Synced Oct 19, 2026, 2:30 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Immunoglobulin, Diagnosis, Evaluation, and Key Learnings Patient Registry (IDEaL™)

NCT01109810
View directory record Official record
Conditions
IVIg or SCIg Therapy in the Home or at Alternate Site
Interventions
Not listed
Lead sponsor
Coram Clinical Trials
Other
Eligibility
Not listed
Enrollment
496 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2022
U.S. locations
1
States / cities
Centennial, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 22, 2022 · Synced Oct 19, 2026, 2:30 PM EDT
Completed Phase 1 Interventional

Intravenous Immunoglobulin (IVIg) for the Treatment of Stiff-Man Syndrome (SMS)

NCT00001550
View directory record Official record
Conditions
Muscle Rigidity, Spasm, Stiff Man Syndrome
Interventions
IVIg
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 14, 2006 · Synced Oct 19, 2026, 2:30 PM EDT
Completed Phase 2 Interventional Results available

Stem Cell Transplant for Immunologic or Histiocytic Disorders

NCT00176865
View directory record Official record
Conditions
Hemophagocytic Lymphohistiocytosis, X-Linked Lymphoproliferative Disorders, Chediak-Higashi Syndrome, Griscelli Syndrome, Immunologic Deficiency Syndromes, Langerhans-Cell Histiocytosis
Interventions
Stem Cell Transplant, Fludarabine, Melphalan, Anti-thymocyte globulin (ATG), Campath 1H, Cyclosporin A, Mycophenolate mofetil, Intravenous immunoglobulin (IVIG)
Procedure · Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 35 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2014
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Oct 19, 2026, 2:30 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Pilot Study for Collection of Anti-Influenza A Immune Plasma

NCT00984451
View directory record Official record
Conditions
Influenza A Virus Infection, Swine Flu
Interventions
Plasma collection following infection or vaccination with influenza A
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years · Male only
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2018
U.S. locations
12
States / cities
Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Oct 19, 2026, 2:30 PM EDT
Recruiting Phase 1Phase 2 Interventional

Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases

NCT04083183
View directory record Official record
Conditions
Non-Malignant Neoplasm
Interventions
Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10, Fludarabine, Cyclophosphamide, Lapine T-Lymphocyte Immune Globulin, Total-Body Irradiation, Hematopoietic Cell Transplantation, Mycophenolate Mofetil, Sirolimus, Bone Marrow Aspiration, Biospecimen Collection
Biological · Drug · Radiation + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 49 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 19, 2026, 2:30 PM EDT
Completed Phase 3 Interventional Results available

A Study to Find How Safe and Effective GAMMAPLEX® is in Subjects With Chronic Idiopathic Thrombocytopenic Purpura (ITP)

NCT00504075
View directory record Official record
Conditions
Chronic Idiopathic Thrombocytopenic Purpura
Interventions
Gammaplex, intravenous immunoglobulin
Biological
Lead sponsor
Bio Products Laboratory
Other
Eligibility
18 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
7
States / cities
Orange City, Florida • Chicago, Illinois • Bethesda, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2013 · Synced Oct 19, 2026, 2:30 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Washington University WU 409: Immune Responses to Rabies Vaccine.

NCT07399951
View directory record Official record
Conditions
Healthy Participants
Interventions
Imovax, RabAvert, HyperRAB
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 19, 2026, 2:30 PM EDT
Recruiting Phase 2 Interventional

Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis

NCT03630211
View directory record Official record
Conditions
Systemic Sclerosis, Diffuse Sclerosis Systemic, Interstitial Lung Disease, Pulmonary Hypertension
Interventions
Cyclophosphamide, Mesna, Rituximab, Alemtuzumab, Thiotepa, GM-CSF, Intravenous immunoglobulin, Total Body Irradiation, Anti Thymocyte Globulin
Drug · Radiation
Lead sponsor
Paul Szabolcs
Other
Eligibility
8 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 19, 2026, 2:30 PM EDT
Completed Phase 2 Interventional

RECOVER-AUTONOMIC: Platform Protocol, Appendix A (IVIG)

NCT06305793
View directory record Official record
Conditions
Long COVID, Long Coronavirus Disease 2019 (Covid19), Long Covid-19
Interventions
IVIG (intravenous immunoglobulin), IVIG Placebo, Coordinated Care, Usual Care
Drug · Behavioral
Lead sponsor
Kanecia Obie Zimmerman
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 19, 2026, 2:30 PM EDT
Not listed Phase 2 Interventional

Safety and Efficacy Study in the Treatment of Intestinal Problems Associated With Autism

NCT00110708
View directory record Official record
Conditions
Autism, Autistic Disorder, Child Development Disorders, Pervasive, Gastrointestinal Diseases, Signs and Symptoms, Digestive
Interventions
Oralgam (human immunoglobulin)
Drug
Lead sponsor
PediaMed Pharmaceuticals
Industry
Eligibility
2 Years to 18 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
22
States / cities
Phoenix, Arizona • Sacramento, California • Gainesville, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2006 · Synced Oct 19, 2026, 2:30 PM EDT
Completed Phase 4 Interventional Results available

Pharmacokinetics, Safety, and Tolerability of Subcutaneous GAMUNEX-C in Pediatric Subjects With Primary Immunodeficiency

NCT01465958
View directory record Official record
Conditions
Primary Immunodeficiency
Interventions
GAMUNEX-C
Biological
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
2 Years to 16 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
4
States / cities
Los Angeles, California • Centennial, Colorado • Hollywood, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2015 · Synced Oct 19, 2026, 2:30 PM EDT
Terminated Phase 4 Interventional Results available

Study to Evaluate the Efficacy and Safety of PANZYGA in Pediatric Patients With Chronic Immune Thrombocytopenia (ITP)

NCT03866798
View directory record Official record
Conditions
Chronic Immune Thrombocytopenia
Interventions
Panzyga
Biological
Lead sponsor
Octapharma
Industry
Eligibility
1 Year to 18 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
8
States / cities
Sacramento, California • Minneapolis, Minnesota • Rochester, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Oct 19, 2026, 2:30 PM EDT
Completed Phase 2 Interventional Results available

Treatment of Multiple System Atrophy Using Intravenous Immunoglobulins

NCT00750867
View directory record Official record
Conditions
Multiple System Atrophy
Interventions
intravenous immunoglobulin (IVIg)
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 19, 2026, 2:30 PM EDT
Completed Phase 3 Interventional Results available

Evaluating the Safety and Efficacy of Anti-Influenza Intravenous Hyperimmune Immunoglobulin (IVIG) in Adults Hospitalized With Influenza

NCT02287467
View directory record Official record
Conditions
Influenza A, Influenza B
Interventions
Intravenous hyperimmune immunoglobulin (IVIG), Placebo for IVIG
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
17
States / cities
San Diego, California • Denver, Colorado • Chicago, Illinois + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2019 · Synced Oct 19, 2026, 2:30 PM EDT
Completed Phase 4 Interventional

A Study to Assess Adults With CIDP Transitioning From IVIg to Efgartigimod PH20 SC

NCT06637072
View directory record Official record
Conditions
Chronic Inflammatory Demyelinating Polyneuropathy
Interventions
Efgartigimod PH20 SC
Biological
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
13
States / cities
Washington D.C., District of Columbia • Maitland, Florida • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 19, 2026, 2:30 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety Study of Intravenous Immunoglobulin (IVIG) Post-Portoenterostomy in Infants With Biliary Atresia

NCT01854827
View directory record Official record
Conditions
Biliary Atresia
Interventions
Intravenous immunoglobulin (IVIG)
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
3 Days to 120 Days
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
6
States / cities
Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 19, 2026, 2:30 PM EDT
Not listed Phase 2 Interventional

Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma

NCT01811368
View directory record Official record
Conditions
Refractory Non Hodgkin Lymphoma, Relapsed Non Hodgkin Lymphoma
Interventions
rituximab, ibritumomab tiuxetan, anti-thymocyte globulin, total nodal irradiation, peripheral blood stem cell transplantation, allogeneic hematopoietic stem cell transplantation, cyclosporine, mycophenolate mofetil
Biological · Radiation · Procedure + 1 more
Lead sponsor
Joseph Tuscano
Other
Eligibility
19 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Nov 30, 2022 · Synced Oct 19, 2026, 2:30 PM EDT
Recruiting Phase 3 Interventional

A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

NCT06533098
View directory record Official record
Conditions
Thrombocytopenia, Neonatal Alloimmune
Interventions
Nipocalimab, Intravenous immunoglobulins (IVIG), Prednisone
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
13
States / cities
Birmingham, Alabama • Sacramento, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 19, 2026, 2:30 PM EDT